KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation
Open accessPublished version of a preprint
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
The first step of RAF activation involves binding to active RAS, resulting in the recruitment of RAF to the plasma membrane. To understand the molecular details of RAS-RAF interaction, we present crystal structures of wild-type and oncogenic mutants of KRAS complexed with the RAS-binding domain (RBD) and the membrane-interacting cysteine-rich domain (CRD) from the N-terminal regulatory region of RAF1. Our structures reveal that RBD and CRD interact with each other to form one structural entity in which both RBD and CRD interact extensively with KRAS. Mutations at the KRAS-CRD interface result in a significant reduction in RAF1 activation despite only a modest decrease in binding affinity. Combining our structures and published data, we provide a model of RAS-RAF complexation at the membrane, and molecular insights into RAS-RAF interaction during the process of RAS-mediated RAF activation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
PHENIX : a comprehensive Python-based system for macromolecular structure solution
Adams, P. D., Afonine, P. V., Bunkóczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L.-W., Kapral, G. J., Grosse-Kunstleve, R. W., et al. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909052925 · Cited by 23,716
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612 · cited 5×
“Wild-type and mutants of KRAS4b(1-169) clones were generated with an upstream tobacco etch virus (TEV) protease site (ENLYFQG), which when cleaved during purification leaves an additional glycine residue at the N-terminus of the KRAS4b protein.”
InfluentialKabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
The Frequency of Ras Mutations in Cancer
Prior, I. A., Hood, F. E., & Hartley, J. L. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3682 · Cited by 1,130
Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design
Ostrem, J. M. L., & Shokat, K. M. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.139 · Cited by 641
Rodriguez-Viciana, P., Sabatier, C., & McCormick, F. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.11.4943-4954.2004 · Cited by 327 · cited 1×
“Total reflections 387,827 (26,517) 264,233 (42,280) 102,583 (16,570) 63,877 (10,610) 354,688 (56,895) 161,066 (24,222)”
Self-citationSarkozy, A., Carta, C., Moretti, S., Zampino, G., Digilio, M. C., Pantaleoni, F., Scioletti, A. P., Esposito, G., Cordeddu, V., Lepri, F., et al. (2009) · Human Mutation · doi:10.1002/humu.20955 · Cited by 303 · cited 5×
“Wild-type and mutants of KRAS4b(1-169) clones were generated with an upstream tobacco etch virus (TEV) protease site (ENLYFQG), which when cleaved during purification leaves an additional glycine residue at the N-terminus of the KRAS4b protein.”
InfluentialInhibition of RAS function through targeting an allosteric regulatory site
Spencer-Smith, R., Koide, A., Zhou, Y., Eguchi, R. R., Sha, F., Gajwani, P., Santana, D., Gupta, A., Jacobs, M., Herrero-Garcia, E., et al. (2017) · Nature Chemical Biology · doi:10.1038/nchembio.2231 · Cited by 283
KRAS Dimerization Impacts MEK Inhibitor Sensitivity and Oncogenic Activity of Mutant KRAS
Ambrogio, C., Köhler, J., Zhou, Z.-W., Wang, H., Paranal, R., Li, J., Capelletti, M., Caffarra, C., Li, S., Lv, Q., et al. (2018) · Cell · doi:10.1016/j.cell.2017.12.020 · Cited by 270
Research works printed but not linked: 41
- Lavoie, H. & Therrien, M. Regulation of RAF protein kinases in ERK signalling. Nat. Rev. Mol. Cell Biol. 16, 281–298 (2015). · DOI · Paper page
- Terrell, E. M. & Morrison, D. K. Ras-mediated activation of the Raf family kinases. Cold Spring Harb. Perspect. Med. 9, a03376 (2019). · DOI · Paper page
- Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nat. Rev. Mol. Cell Biol. 5, 875–885 (2004). · DOI · Paper page
- Park, E. et al. Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes. Nature 575, 545–550 (2019). · DOI · Paper page
- Fang, Z. et al. Multivalent assembly of KRAS with the RAS-binding and cysteine-rich domains of CRAF on the membrane. Proc Natl Acad Sci USA 117, 12101–12108 (2020). · DOI · Paper page
- Improta-Brears, T., Ghosh, S. & Bell, R. M. Mutational analysis of Raf-1 cysteine rich domain: requirement for a cluster of basic aminoacids for interaction with phosphatidylserine. Mol. Cell Biochem. 198, 171–178 (1999). · DOI
- Travers, T. et al. Molecular recognition of RAS/RAF complex at the membrane: role of RAF cysteine-rich domain. Sci. Rep. 8, 8461 (2018). · DOI
- Brtva, T. R. et al. Two distinct Raf domains mediate interaction with Ras. J. Biol. Chem. 270, 9809–9812 (1995). · DOI · Paper page
- Daub, M. et al. The RafC1 cysteine-rich domain contains multiple distinct regulatory epitopes which control Ras-dependent Raf activation. Mol. Cell Biol. 18, 6698–6710 (1998). · DOI
- Drugan, J. K. et al. Ras interaction with two distinct binding domains in Raf-1 may be required for Ras transformation. J. Biol. Chem. 271, 233–237 (1996). · DOI
- Hu, C. D. et al. Cysteine-rich region of Raf-1 interacts with activator domain of post-translationally modified Ha-Ras. J. Biol. Chem. 270, 30274–30277 (1995). · DOI
- Thapar, R., Williams, J. G. & Campbell, S. L. NMR characterization of full-length farnesylated and non-farnesylated H-Ras and its implications for Raf activation. J. Mol. Biol. 343, 1391–1408 (2004). · DOI
- Williams, J. G. et al. Elucidation of binding determinants and functional consequences of Ras/Raf-cysteine-rich domain interactions. J. Biol. Chem. 275, 22172–22179 (2000). · DOI
- Bondeva, T., Balla, A., Varnai, P. & Balla, T. Structural determinants of Ras-Raf interaction analyzed in live cells. Mol. Biol. Cell 13, 2323–2333 (2002). · DOI
- Cutler, R. E. Jr, Stephens, R. M., Saracino, M. R. & Morrison, D. K. Autoregulation of the Raf-1 serine/threonine kinase. Proc. Natl Acad. Sci. USA 95, 9214–9219 (1998). · DOI · Paper page
- Okada, T. et al. The strength of interaction at the Raf cysteine-rich domain is a critical determinant of response of Raf to Ras family small GTPases. Mol. Cell Biol. 19, 6057–6064 (1999). · DOI
- Roy, S., Lane, A., Yan, J., McPherson, R. & Hancock, J. F. Activity of plasma membrane-recruited Raf-1 is regulated by Ras via the Raf zinc finger. J. Biol. Chem. 272, 20139–20145 (1997). · DOI
- Fetics, S. K. et al. Allosteric effects of the oncogenic RasQ61L mutant on Raf-RBD. Structure 23, 505–516 (2015). · DOI · Paper page
- Mott, H. R. et al. The solution structure of the Raf-1 cysteine-rich domain: a novel ras and phospholipid binding site. Proc. Natl Acad. Sci. USA 93, 8312–8317 (1996). · DOI · Paper page
- Nassar, N. et al. Ras/Rap effector specificity determined by charge reversal. Nat. Struct. Biol. 3, 723–729 (1996). · DOI · Paper page
- Kondo, Y. et al. Cryo-EM structure of a dimeric B-Raf:14-3-3 complex reveals asymmetry in the active sites of B-Raf kinases. Science 366, 109–115 (2019). · DOI · Paper page
- Nakhaeizadeh, H., Amin, E., Nakhaei-Rad, S., Dvorsky, R. & Ahmadian, M. R. The RAS-effector interface: isoform-specific differences in the effector binding regions. PLoS ONE 11, e0167145 (2016). · DOI · Paper page
- Li, S., Jang, H., Zhang, J. & Nussinov, R. Raf-1 cysteine-rich domain increases the affinity of K-Ras/Raf at the membrane, promoting MAPK signaling. Structure 26, 513–525 e2 (2018). · DOI
- Block, C., Janknecht, R., Herrmann, C., Nassar, N. & Wittinghofer, A. Quantitative structure-activity analysis correlating Ras/Raf interaction in vitro to Raf activation in vivo. Nat. Struct. Biol. 3, 244–251 (1996). · DOI
- Ghosh, S. et al. The cysteine-rich region of raf-1 kinase contains zinc, translocates to liposomes, and is adjacent to a segment that binds GTP-ras. J. Biol. Chem. 269, 10000–10007 (1994). · DOI · Paper page
- Neale, C. & Garcia, A. E. The plasma membrane as a competitive inhibitor and positive allosteric modulator of KRas4B signaling. Biophys. J. 118, 1129–1141 (2020). · DOI · Paper page
- Li, Z. L., Prakash, P. & Buck, M. A “Tug of War” maintains a dynamic protein-membrane complex: molecular dynamics simulations of C-Raf RBD-CRD bound to K-Ras4B at an anionic membrane. ACS Cent. Sci. 4, 298–305 (2018). · DOI
- Haling, J. R. et al. Structure of the BRAF-MEK complex reveals a kinase activity independent role for BRAF in MAPK signaling. Cancer Cell 26, 402–413 (2014). · DOI · Paper page
- Liau, N. P. D. et al. Negative regulation of RAF kinase activity by ATP is overcome by 14-3-3-induced dimerization. Nat. Struct. Mol. Biol. 27, 134–141 (2020). · DOI
- Thorson, J. A. et al. 14-3-3 proteins are required for maintenance of Raf-1 phosphorylation and kinase activity. Mol. Cell Biol. 18, 5229–5238 (1998). · DOI · Paper page
- Hu, J. et al. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell 154, 1036–1046 (2013). · DOI · Paper page
- Rushworth, L. K., Hindley, A. D., O’Neill, E. & Kolch, W. Regulation and role of Raf-1/B-Raf heterodimerization. Mol. Cell Biol. 26, 2262–2272 (2006). · DOI · Paper page
- Weber, C. K., Slupsky, J. R., Kalmes, H. A. & Rapp, U. R. Active Ras induces heterodimerization of cRaf and BRaf. Cancer Res. 61, 3595–3598 (2001).
- Esposito, D., Garvey, L. A. & Chakiath, C. S. Gateway cloning for protein expression. Methods Mol. Biol. 498, 31–54 (2009). · DOI
- Lakshman, B. et al. Quantitative biophysical analysis defines key components modulating recruitment of the GTPase KRAS to the plasma membrane. J. Biol. Chem. 294, 2193–2207 (2019). · DOI · Paper page
- Kopra, K. et al. Homogeneous dual-parametric-coupled assay for simultaneous nucleotide exchange and KRAS/RAF-RBD interaction monitoring. Anal. Chem. 92, 4971–4979 (2020). · DOI
- Dharmaiah, S. et al. Structures of N-terminally processed KRAS provide insight into the role of N-acetylation. Sci. Rep. 9, 10512 (2019). · DOI
- Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486–501 (2010). · DOI · Paper page
- Sievers, F. et al. Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol. Syst. Biol. 7, 539 (2011). · DOI · Paper page
- Robert, X. & Gouet, P. Deciphering key features in protein structures with the new ENDscript server. Nucleic Acids Res. 42, W320–W324 (2014). · DOI · Paper page
- Morin, A. et al. Collaboration gets the most out of software. Elife 2, e01456 (2013). · DOI · Paper page
Cited by
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
“95,96 RAF activation fi rst requires the translocation of RAF from the cytosol to the plasma membrane, which represents a vital step.”
BackgroundAnti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor
Hallin, J., Bowcut, V., Calinisan, A., Briere, D. M., Hargis, L., Engstrom, L. D., Laguer, J., Medwid, J., Vanderpool, D., Lifset, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02007-7 · Cited by 553
Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS
Schulze, C. J., Seamon, K. J., Zhao, Y., Yang, Y. C., Cregg, J., Kim, D., Tomlinson, A., Choy, T. J., Wang, Z., Sang, B., et al. (2023) · Science · doi:10.1126/science.adg9652 · Cited by 264
BRAF — a tumour-agnostic drug target with lineage-specific dependencies
Hanrahan, A. J., Chen, Z., Rosen, N., & Solit, D. B. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00852-0 · Cited by 136
Cryo-EM structure of a RAS/RAF recruitment complex
Park, E., Rawson, S., Schmoker, A., Kim, B.-W., Oh, S., Song, K., Jeon, H., & Eck, M. J. (2023) · Nature Communications · doi:10.1038/s41467-023-40299-6 · Cited by 51
Metadata
- Authors
- Tran, T. H., Chan, A. H., Young, L. C., Bindu, L., Neale, C., Messing, S., Dharmaiah, S., Taylor, T., Denson, J.-P., Esposito, D., Nissley, D. V., Stephen, A. G., McCormick, F., & Simanshu, D. K.
- Venue
- Nature Communications
- Published
- 2021-02-19
- Volume
- 12
- Issue
- 1
- Pages
- 1176-1176
- ISSN
- 2041-1723 (ISSN-L)
- OpenAlex
- W3131852822
- Cited by
- 243
- References
- 12
- FWCI
- 10.26
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Funders
- U.S. Department of Health & Human Services | NIH | National Cancer Institute (HHSN261200800001E)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation. https://app.cochat.ai/papers/10.1038/s41467-021-21422-x
- The paper
- Tran, T. H., Chan, A. H., Young, L. C., Bindu, L., Neale, C., Messing, S., Dharmaiah, S., Taylor, T., Denson, J.-P., Esposito, D., Nissley, D. V., Stephen, A. G., McCormick, F., & Simanshu, D. K. (2021). KRAS interaction with RAF1 RAS-binding domain and cysteine-rich domain provides insights into RAS-mediated RAF activation. Nature Communications. https://doi.org/10.1038/s41467-021-21422-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.